Combined Immunohistochemistry after Mass Spectrometry Imaging for Superior Spatial Information.


Journal

Proteomics. Clinical applications
ISSN: 1862-8354
Titre abrégé: Proteomics Clin Appl
Pays: Germany
ID NLM: 101298608

Informations de publication

Date de publication:
01 2019
Historique:
received: 01 03 2018
revised: 04 07 2018
pubmed: 24 7 2018
medline: 4 4 2019
entrez: 24 7 2018
Statut: ppublish

Résumé

Tissue slides analyzed by MS imaging (MSI) are stained by H&E (Haematoxylin and Eosin) to identify regions of interest. As it can be difficult to identify specific cells of interest by H&E alone, data analysis may be impaired. Immunohistochemistry (IHC) can highlight cells of interest but single or combined IHC on tissue sections analyzed by MSI have not been performed. We performed MSI on bone marrow biopsies from patients with multiple myeloma and stained different antibodies (CD38, CD138, MUM1, kappa- and lambda). A combination of CK5/6/TTF1 and Napsin-A/p40 is stained after MSI on adenocarcinoma and squamous cell carcinoma of the lung. Staining intensities of p40 after MSI and on a serial section are quantified on a tissue microarray (n = 44) by digital analysis. Digital evaluation reveals weaker staining intensities after MSI as compared to serial sections. Staining quality and quantity after MSI enables to identify cells of interest. On the tissue microarray, one out of 44 tissue specimens shows no staining of p40 after MSI, but weak nuclear staining on a serial section. We demonstrated that single and double IHC staining is feasible on tissue sections previously analyzed by MSI, with decreased staining intensities.

Identifiants

pubmed: 30035857
doi: 10.1002/prca.201800035
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1800035

Informations de copyright

© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Auteurs

Katharina Kriegsmann (K)

Department of Hematology, Oncology and Rheumatology, University of Heidelberg, 69117, Heidelberg, Germany.

Rémi Longuespée (R)

Institute of Pathology, University of Heidelberg, 69117 Heidelberg, Germany.

Michael Hundemer (M)

Department of Hematology, Oncology and Rheumatology, University of Heidelberg, 69117, Heidelberg, Germany.

Christiane Zgorzelski (C)

Institute of Pathology, University of Heidelberg, 69117 Heidelberg, Germany.

Rita Casadonte (R)

Proteopath Trier, 54296 Trier, Germany.

Kristina Schwamborn (K)

Institute of Pathology, TU Munich, 80333 Munich, Germany.

Wilko Weichert (W)

Institute of Pathology, TU Munich, 80333 Munich, Germany.

Peter Schirmacher (P)

Institute of Pathology, University of Heidelberg, 69117 Heidelberg, Germany.

Alexander Harms (A)

Institute of Pathology, University of Heidelberg, 69117 Heidelberg, Germany.

Daniel Kazdal (D)

Institute of Pathology, University of Heidelberg, 69117 Heidelberg, Germany.

Jonas Leichsenring (J)

Institute of Pathology, University of Heidelberg, 69117 Heidelberg, Germany.

Albrecht Stenzinger (A)

Institute of Pathology, University of Heidelberg, 69117 Heidelberg, Germany.

Arne Warth (A)

Institute of Pathology, University of Heidelberg, 69117 Heidelberg, Germany.

Margaux Fresnais (M)

Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, 69120 Heidelberg, Germany.
German Cancer Consortium (DKTK)-German Cancer Research Center (DKFZ), 69117 Heidelberg, Germany.

Jörg Kriegsmann (J)

Proteopath Trier, 54296 Trier, Germany.

Mark Kriegsmann (M)

Institute of Pathology, University of Heidelberg, 69117 Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH